These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers. Arnt J Eur J Pharmacol; 1983 Jul; 91(2-3):273-8. PubMed ID: 6617748 [TBL] [Abstract][Full Text] [Related]
9. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system. Hjorth S Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. Eriksson E; Modigh K; Carlsson A; Wikström H Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196 [TBL] [Abstract][Full Text] [Related]
11. Stereoselective inhibition of prolactin secretion by (-)-HW-165, a novel 3-PPP congener; further support for similarities between central DA autoreceptors and pituitary lactotroph DA receptors. Hjorth S; Eriksson E; Andersson B Eur J Pharmacol; 1986 Jun; 125(3):421-8. PubMed ID: 3755402 [TBL] [Abstract][Full Text] [Related]
12. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors. Claustre Y; Fage D; Zivkovic B; Scatton B J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197 [TBL] [Abstract][Full Text] [Related]
13. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers. Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. Martin GE; Haubrich DR; Williams M Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920 [TBL] [Abstract][Full Text] [Related]
15. Partial protection against hyperbaric oxygen induced convulsions by dopaminergic agents in mice: possible involvement of autoreceptors? Criborn CO; Henriksson C; Ahlenius S; Hillegaart V J Neural Transm; 1987; 69(3-4):277-85. PubMed ID: 3625196 [TBL] [Abstract][Full Text] [Related]
16. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation. Oberlander C; Boissier JR J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905 [TBL] [Abstract][Full Text] [Related]
17. Assessment of dopamine autoreceptor agonist properties of apomorphine, (+)-3-PPP and (-)-3-PPP by recording of yawning behaviour in rats. Ståhle L; Ungerstedt U Eur J Pharmacol; 1984 Feb; 98(2):307-10. PubMed ID: 6714314 [TBL] [Abstract][Full Text] [Related]
18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine. Clark D; Salah RS; Galloway MP Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667 [TBL] [Abstract][Full Text] [Related]
19. Differential electrophysiological effects of 3-PPP and its enantiomers on dopamine autoreceptors and postsynaptic receptors. Bergstrom DA; Carlson JH; Bromley SD; Jackson DM; Walters JR Eur J Pharmacol; 1986 May; 124(1-2):75-84. PubMed ID: 3720847 [TBL] [Abstract][Full Text] [Related]
20. Effects of intraperitoneal administration of apomorphine and the isomers of 3-(1-propyl-3-piperidinyl)phenol on the firing activity of substantia nigra dopamine neurons: comparison of agonist efficacies and development of acute tolerance. Meltzer LT; Christoffersen CL Neuropharmacology; 1988 Sep; 27(9):933-42. PubMed ID: 3185867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]